Get started
Tenax Therapeutics, Inc.Tenax Therapeutics, Inc.Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

TENX trade ideas

TENX - Catalyst 03/06/2024 - Possible gap fillTenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction. This is not a financial advice! Upcoming catalysts 03/06/2024 We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. Keep an eye on 5.6 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains. SL under 4.3 TPs approx. 8.3 (gap fill) Most info on the chart. Trade carefully!
NASDAQ:TENXLong
by meitshels_smell_trades
$TENX is gonna fall todayPupm&Dump trading strategy idea. $TENX is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,00; stop-loss — $2,78; take-profit — $1,22; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:TENXShort
by KozakHlib
TENX - facing resistance for the 3rd time in the short periodCompany currently in the process of development of levosimendan for Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Efforts included a successful pre-IND meeting with the FDA in April 2018, which allowed the existing Phase II clinical protocol to be used for PH-HFpEF. During the summer and fall, the company identified clinical trial sites, obtained approvals from institutional review boards (IRBs) and executed on contracting and scheduling. Prior to year end, the first site was activated and the first patient in the Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF or HELP trial was enrolled in March 2019. The company also closed a $10 million capital raise in December, providing funds in support of the HELP trial which should be sufficient to complete the end of Phase II meeting.
NASDAQ:TENX
by bobik99